Review article: A clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 5, 2013, Pages 447-459

  Khanna, R ^a   Sattin, B D ^b   Afif, W ^c   Benchimol, E I ^d   Bernard, E J ^e   Bitton, A ^c   Bressler, B ^f   Fedorak, R N ^g   Ghosh, S ^h   Greenberg, G R ⁱ   Marshall, J K ^j   Panaccione, R ^h   Seidman, E G ^k   Silverberg, M S ⁱ   Steinhart, A H ⁱ   Sy, R ^l   Van Assche, G ⁱ   Walters, T D ^m   Sandborn, W J ⁿ   Feagan, B G ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b Janssen Inc   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j MCMASTER UNIVERSITY   (Canada)

^k MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^l UNIVERSITY OF OTTAWA   (Canada)

^m HOSPITAL FOR SICK CHILDREN   (Canada)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DRUG ANTIBODY; INFLIXIMAB; METHOTREXATE; PLACEBO;

ANTIBODY PRODUCTION; ARTICLE; CLINICAL PRACTICE; CROHN DISEASE; DISEASE COURSE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOGENICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 84882454346     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12407     Document Type: Article

References (48)

1. Derkx B, Taminiau J, Radema S, et al,. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173-4.
2. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ,. Review article: infliximab for Crohn's disease treatment-shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011; 33: 857-69.
3. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S,. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 674-88.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
5. Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
6. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
7. Kopylov U, Mantzaris GJ, Katsanos KH, et al,. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011; 33: 349-57.
8. Sandborn WJ, Rutgeerts P, Enns R, et al,. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
9. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG,. A test-based strategy is more cost effective than empiric dose-escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013; 11: 654-66.
10. Colombel JF, Rutgeerts P, Malchow H, et al,. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001; 49: 42-6.
11. Danese S,. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012; 61: 918-32.
12. Leiper K, Martin K, Ellis A, et al,. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011; 60: 1520-6.
13. Sandborn WJ, Colombel JF, Sands BE, et al,. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012; 143: 62-9.
14. Ben-Horin S, Chowers Y,. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987-95.
15. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J,. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-Alpha antibodies. Scand J Gastroenterol 2009; 44: 774-81.
16. Cassinotti A, Travis S,. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-75.
17. Chaparro M, Guerra I, Munoz-Linares P, Gisbert JP,. Systematic review: antibodies and anti-TNF-Alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 971-86.
18. Colombel JF, Feagan BG, Sandborn WJ, Van AG, Robinson AM,. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 349-58.
19. Miheller P, Kiss LS, Lorinczy K, Lakatos PL,. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opin Biol Ther 2012; 12: 179-92.
20. Ordas I, Feagan BG, Sandborn WJ,. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10: 1079-87.
21. Afif W, Loftus EV Jr, Faubion WA, et al,. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
22. Maser EA, Villela R, Silverberg MS, Greenberg GR,. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54.
23. Pariente B, de Pineton CG, Krzysiek R, et al,. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1199-206.
24. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
25. Baert F, Noman M, Vermeire S, et al,. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
26. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P,. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
27. Reinisch, W, Feagan, BG, Rutgeerts, PJ, et al,. Infliximab concentration and clinical outcome in patients with ulcerative colitis. Gastroenterology 2012; 142: S-114.
28. Hanauer SB, Wagner CL, Bala M, et al,. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
29. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al,. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8.
30. Ordas I, Mould DR, Feagan BG, Sandborn WJ,. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46.
31. Rolink AG, Schaniel C, Andersson J, Melchers F,. Selection events operating at various stages in B cell development. Curr Opin Immunol 2001; 13: 202-7.
32. Rajewsky K,. Clonal selection and learning in the antibody system. Nature 1996; 381: 751-8.
33. Schellekens H, Casadevall N,. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004; 251 (Suppl. 2): II4-II9.
34. Rutgeerts P, Feagan BG, Lichtenstein GR, et al,. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13.
35. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
36. Wang SL, Ohrmund L, Hauenstein S, et al,. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012; 382: 177-88.
37. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T,. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-9.
38. Feagan BG, McDonald JW, Panaccione R, et al,. Methotrexate for the prevention of antibodies to infliximab in patients with Crohn's disease. Gastroenterology 2010; 138: S167-8.
39. Cornillie F, Hanauer S, Diamond RH, et al,. Early serum infliximab trough level, clinical disease activity and CRP as markers of sustained benefit of infliximab treatment in Crohn's disease: a post-hoc analysis of the ACCENT1 trial. Am J Gastroenterol 2011; 106: S462-3.
40. Murthy, SK, Kevans, D, Seow, CH, et al,. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome in acute ulcerative colitis. Gastroenterology 2012; 142: S-388.
41. Fasanmade AA, Adedokun OJ, Ford J, et al,. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009; 65: 1211-28.
42. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM,. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010; 48: 297-308.
43. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM,. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011; 33: 946-64.
44. Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y,. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 2010; 16: 1898-904.
45. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P,. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24.
46. Vande Casteele N, Gils A, Singh S, et al,. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962-71.
47. Feagan, BG, Singh, S, Lockton, S, et al,. Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease (CD). Gastroenterology 2012; 142: S-114.
48. Jamnitski A, Bartelds GM, Nurmohamed MT, et al,. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011; 70: 284-8.